Revvity Inc

Revvity Inc (RVTY) Stock Analysis

$154.710

+2.630 (+1.70%)At close

Loading chart…
High
156.860
Open
151.910
VWAP
153.47
Volume
2.37M
Mkt Cap
13.04B
Low
148.830
Amount
364.46M
EV/EBITDA, TTM
21.21

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

AI analysis of Revvity Inc (RVTY)

Buy

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

Valuation Metrics

The current forward P/E ratio for Revvity Inc (RVTY) is 24.15, compared to its 5-year average forward P/E of 22.13.

Forward P/E

Fair
5Y Average P/E
22.13
Current P/E
24.15
Overvalued
25.11
Undervalued
19.14

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
18.11
Current EV/EBITDA
21.21
Overvalued
20.56
Undervalued
15.66

Forward P/S

Overvalued
5Y Average P/S
4.58
Current P/S
5.75
Overvalued
5.29
Undervalued
3.87

Alphio AI Price Scenarios for RVTY

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%RVTY

$80.72

Scenario price

B

Base

Base · 50%RVTY

$80.47

Scenario price

B

Bear

Bear · 25%RVTY

$65.23

Scenario price

Whales holding RVTY

C

Campbell & Company, LP

+ HoldingRVTY

+8.93%

3M Return

M

Meridiem Capital Partners LP

+ HoldingRVTY

+5.65%

3M Return

E

EdgePoint Investment Group Inc.

+ HoldingRVTY

+4.51%

3M Return

V

Vaughan Nelson Investment Management, L.P.

+ HoldingRVTY

+2.68%

3M Return

P

Port Capital LLC

+ HoldingRVTY

-1.53%

3M Return

Events Timeline

2026-09-24 (ET)

10:00:00

Everpure Stock Rises $20.86 to $130.51

08:30:00

Revvity Launches GSP T1D 3plex Detection Kit

2026-09-15 (ET)

10:00:00

Skyworks and Others See Notable Stock Gains

2026-09-09 (ET)

06:30:00

Revvity Acquires French Biotech Company HCD

2026-08-04 (ET)

06:30:00

Revvity Reports Q2 Revenue of $730M

News

RVTY FAQ — answered by Alphio AI

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading